The CJC-1295 studies cited across this digest

How to read this CJC-1295 reference list

These are the sources behind the CJC-1295 digest. The core human pharmacokinetic findings come from Teichman 2006 ^[3] and Ionescu/Frohman 2006 ^[1]; the albumin-bioconjugate origin from Jette 2005 ^[2]; the once-daily GHRH-knockout growth result from Alba 2006 ^[4]; the serum-proteome biomarkers from Sackmann-Sala 2009 ^[5]; and the class synthesis from the 2025 Nature Reviews Endocrinology review ^[14]. The GHRH-GHRP synergy and secretagogue-pulsatility supporting work is listed below them. Each entry carries a DOI or PubMed link for verification.

The list is deliberately weighted toward primary literature: peer-reviewed pharmacokinetic and mechanistic studies, a review in a high-impact endocrinology journal, and the analytical-chemistry paper that identified CJC-1295 in a seized preparation ^[6]. Where a finding on this site is quantitative — a half-life, a fold-change, a dose, a duration — it traces to one of these entries by its bracketed number. Where the site marks an absence (no long-term safety trial, no combination efficacy trial), that absence is a statement about this same body of literature, not an oversight in the list.